QualityStocksNewsBreaks Archives - Page 518 of 1422

FridayDec 03, 2021 11:43 am

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), Announces Participation in December 2021 Conferences

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, will be featured in several upcoming conferences. The company announced that president and CEO Kelsey Ramsden has been invited to present in four virtual conferences scheduled in December. Those conferences include the H.C. Wainwright's second annual Psychedelics Conference, the Psychedelics Now Virtual Conference, the #CanndoraConnect: Women in Psychedelics Conference, and the Life Sciences Investor Forum. The H.C. Wainwright Psychedelics Conference is scheduled for Dec. 6, 2021; Ramsden’s presentation will begin at 7 a.m. The Psychedelics Now Virtual Conference will be held…

FridayDec 03, 2021 11:27 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at 2nd Annual H.C. Wainwright Psychedelics Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the Second Annual H.C. Wainwright Psychedelics Conference. The event is slated to be held virtually on Dec. 6, 2021. Tryp’s chairman and CEO Greg McKee will provide an overview of the business and its pipeline, including the upcoming phase 2a clinical trials in fibromyalgia, phantom limb pain, binge eating disorder and other indications. McKee's presentation will be available on-demand through the H.C. Wainwright conference portal beginning at 7:00 a.m. ET. on Monday, Dec.…

FridayDec 03, 2021 9:37 am

QualityStocksNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Announces Upcoming Sequire Clean Tech & EV Virtual Conference

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, will be hosting the first-ever Sequire Clean Tech & EV Conference. The investor event will be held on Dec. 6, 2021. This premier gathering is designed to feature a variety of companies, including those in the EV, energy and power, materials and chemicals, and food and agriculture industries. Green energy and sustainability are becoming top priorities in today’s world, and this inaugural gathering is designed to create an invaluable opportunity for premier innovators in the clean-tech space to…

ThursdayDec 02, 2021 1:27 pm

QualityStocksNewsBreaks – Excellon Resources Inc.’s (NYSE American: EXN) (TSX: EXN) (FSE: E4X2) Platosa Marks 4th Quarter of >21,000 Tons Mined and Milled

Excellon Resources (NYSE American: EXN) (TSX: EXN) (FSE: E4X2) is a diversified metals producer with a precious metals growth pipeline that includes Mexico’s Platosa Mine, Kilgore, a high-quality gold development project in Idaho, as well as and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany boasting more than 750 years of mining history. The company recently released details of its robust second-quarter production numbers generated from its Durango, Mexico-based Platosa Mine. “Excellon saw silver production of 296,013 ounces, lead production of 1.9 million pounds and zinc production of 2.5 million pounds — in aggregate totaling…

ThursdayDec 02, 2021 12:38 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, blood pressure findings from HYPER-H21-3 will be reportable by the end of January 2022 and will contribute to the HYPER-H21-4. The study protocols for HYPER-H21-4 are being readied for submission to the Independent Review Board (“IRB”), and approval is expected by January 2022. HYPER-H21-4, which…

ThursdayDec 02, 2021 12:03 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Switzerland Ethics Committee Approval of Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has received approval from the Switzerland Ethics Committee (swissethics) — the first approval of its kind from a European ethics committee — for its study of Berubicin. Exclusive to CNS Pharmaceuticals, Berubicin is the first anthracycline that appears to cross the blood-brain barrier; the substance is being assessed in a global study designed to evaluate efficacy and safety in the treatment of recurrent glioblastoma multiforme (“GBM”). The adaptive, multicenter, open-label, randomized and controlled study…

ThursdayDec 02, 2021 11:42 am

QualityStocksNewsBreaks – Simply Sonoma Enters Growing CBD-Infused Beverages Space

Simply Sonoma, a company committed to offering CBD products for the environmentally conscious consumer, is branching out into the beverage space with an alcohol-free, CBD wine product as well as a Pinot Noir/CBD sparkling product. A Facts and Factors report expects that the global CBD-infused beverages market will grow at a CAGR of approximately 27.5% between 2021 and 2026, driven by the rising authorization and certification for recreational cannabis in countries such as the United States and Canada (https://ibn.fm/rQu00). Furthermore, there is a growing movement away from smoking cannabis and adopting healthier edible options because of the increasing incidence of…

ThursdayDec 02, 2021 11:31 am

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Plans Opening of Two Additional Ketamine Wellness Centers

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that subsidiary Ketamine Wellness Centers (“KWC”) is planning to open new clinics in Salt Lake City, Utah, and Reno, Nevada; the clinics are slated to open by February 2022. The new clinics will bring the total of KWC locations to 12; the company currently has 10 ketamine infusion treatment clinics in eight different states and is positioned as the largest chain of wellness centers in the country. The Utah location will be one of KWC’s largest clinics, and the Reno clinic is strategically…

ThursdayDec 02, 2021 10:28 am

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Receives Initial Orders from Mexico, Spain

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is expanding internationally. The company’s Flora Beauty division received its first-ever orders for its Mind Naturals and Awe CBD skincare brands for the Spanish and Mexican markets; the company plans to ship the product this month. Flora Beauty’s Mind Naturals brand is designed with young consumers who are just starting a skincare routine while its the AWE brand targets consumers who value customized and personal experiences. The Mind Naturals line was recently named a top-12 finalist in a global pitch competition sponsored by Glosswire. The…

ThursdayDec 02, 2021 10:01 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its receipt of confirmation from the U.S. Food and Drug Administration (“FDA”) that its review of Tryp’s Investigational New Drug (“IND”) application is complete and that the company may proceed with its clinical study in fibromyalgia. The trial, which the company expects to initiate in 2022, is being conducted with Kevin Boehnke, Ph.D. from the University of Michigan and will evaluate Tryp’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. “The upcoming phase 2a study with…

Site Search

Company Search

Category: QualityStocksNewsBreaks